Insider Trading March 19, 2026

Alignment Healthcare CHRO Disposes $425k in Shares Across Two Transactions

Andreas P. Wagner completes structured sales tied to RSU withholding and a 10b5-1 plan; ALHC ownership and recent company results detailed

By Avery Klein ALHC
Alignment Healthcare CHRO Disposes $425k in Shares Across Two Transactions
ALHC

Alignment Healthcare Chief Human Resources Officer Andreas P. Wagner sold a combined 23,602 shares of the company's common stock in two transactions on March 18 and 19, 2026, generating approximately $425,476 in proceeds. One sale covered tax withholding on vested restricted stock units and was non-discretionary; the other was executed under a pre-arranged 10b5-1 trading plan adopted in November 2025. After the trades Wagner owns 148,628 shares. The article also summarizes recent company financial metrics, analyst views, and a pending secondary offering from an affiliate of General Atlantic.

Key Points

  • Andreas P. Wagner sold 23,602 shares of Alignment Healthcare common stock on March 18-19, 2026, generating approximately $425,476.
  • One sale on March 18 covered tax withholding obligations related to vested restricted stock units and was non-discretionary; the March 19 sale was executed under a 10b5-1 plan adopted on November 21, 2025.
  • Alignment Healthcare reported strong Q4 metrics, including a 25% year-over-year membership increase and 44.4% revenue growth; analysts cited by InvestingPro project 2026 EPS of $0.46 and several firms reiterated positive ratings and price targets.

Insider sales and mechanics

Andreas P. Wagner, Chief Human Resources Officer at Alignment Healthcare, Inc. (NASDAQ: ALHC), sold a total of 23,602 shares of the company's common stock across two trades that generated roughly $425,476 in total proceeds.

On March 18, 2026, Wagner disposed of 12,000 shares at a weighted-average price of $17.84, producing $214,080 in gross proceeds. The reported transaction price range for that lot was $17.40 to $18.24. The company filing states this sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units and was not a discretionary trade.

The following day, March 19, 2026, Wagner sold an additional 11,602 shares at a weighted-average price of $18.2207, yielding $211,396. Prices in that transaction ranged from $18.18 to $18.30. That sale was carried out pursuant to a pre-arranged 10b5-1 trading plan adopted on November 21, 2025.

Post-transaction ownership

After these two transactions, Wagner directly holds 148,628 shares of Alignment Healthcare common stock.

Market context and valuation notes

The stock is trading at $18.16. InvestingPro analysis cited in company commentary indicates that Alignment Healthcare is trading below its Fair Value estimate. InvestingPro Tips referenced in the filings show that analysts predict the company will be profitable in 2026, with an EPS forecast of $0.46 for that year. The firm has recorded strong top-line momentum, with revenue rising 46% over the last twelve months according to the same set of disclosures.

Recent operational and analyst updates

Alignment Healthcare reported a strong fourth-quarter performance highlighted by a 25% year-over-year increase in membership and a 44.4% increase in revenue, which exceeded expectations. Management reported a medical benefit ratio of 87.7% and an overall improvement in the selling, general, and administrative expense ratio to 9.7%.

Following those results, Raymond James reiterated a Strong Buy rating with a $27.00 price target, and Piper Sandler maintained an Overweight rating with a $30.00 price target.

Secondary offering and share supply

An affiliate of General Atlantic, L.P. announced a secondary offering of 13.2 million shares of Alignment Healthcare common stock at $19.46 per share. J.P. Morgan is listed as the underwriter for that offering. The disclosure notes the transaction will not provide any proceeds to Alignment Healthcare and that the offering is expected to close on March 4, 2026, subject to customary closing conditions.

Investor resources

For investors seeking additional analysis, the company note references a detailed Pro Research Report available on InvestingPro, covering this company and more than 1,400 other U.S. equities.

Conclusion

The transactions by Alignment Healthcare's CHRO combined a non-discretionary tax-withholding sale tied to vested restricted stock units and a planned sale executed under a 10b5-1 program. Those trades left Wagner with direct ownership of 148,628 shares while the company continues to be the subject of analyst coverage, reported quarterly strength, and a pending secondary offering from a strategic affiliate.


Note: This article relays details reported in company filings and analyst commentary referenced in those filings.

Risks

  • The secondary offering of 13.2 million shares by an affiliate of General Atlantic, L.P. is subject to customary closing conditions, creating uncertainty about the timing and completion of that transaction - this affects public equity markets.
  • Analyst forecasts cited in company commentary, including a projected 2026 EPS of $0.46, are forward-looking estimates and carry the usual uncertainty associated with earnings projections - this impacts investor expectations in the healthcare equity space.
  • A portion of the insider selling was non-discretionary (tax withholding on vested RSUs) and another portion was executed under a pre-arranged 10b5-1 plan, which can limit the degree to which these sales reflect management sentiment - this introduces interpretive uncertainty for market participants evaluating insider activity.

More from Insider Trading

Klaviyo Director Executes $3.8M Sale, Converts Series A to Series B as Company Rolls Out $500M Buyback Mar 19, 2026 BFI Co. liquidates 19,980 Phibro Animal Health shares for about $1.19M under Rule 10b5-1 plan Mar 19, 2026 NextNav COO Sells $57K in Stock as Company Highlights Liquidity and PNT Progress Mar 19, 2026 Director Erik D. Ragatz Boosts Stake in Grocery Outlet with $486,382 Purchase Mar 19, 2026 Silvaco Group insider Pesic Illiya I. reduces holdings in two sales, later receives nominal stock award Mar 19, 2026